At a glance
ClinicalIndex Comparison RecordN/ACompleted· 98,832 enrolled
Drug / intervention
no intervention +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevalence and Incidence of Underlying Disease Diagnosed in Men With Erectile Dysfunction When Prescribed a PDE5i for the First Time
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jun 25, 2010·Updated Jul 19, 2021
In Brief
An observational study evaluating no intervention for Erectile Dysfunction and 2 related conditions. Completed, enrolled 98,832 participants.
Detailed Summary
Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescribed a PDE5 inhibitor for ED more likely to have a new diagnosis of underlying medical conditions compared to men of a similar age not receiving PDE5 inhibitor treatment?
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionJul 2010
Study CompletionAug 2010
TodayJul 2026
First PostedJun 25, 2010
Enrollment StartMay 1, 2010
Primary CompletionJul 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.0 years ago
Interventions
no interventionother
non-interventional study
no interventionother
non-interventional study